Accomplishment

Patent rewards: Applications in
type 2 diabetes and diabetic
wound healing.

USPTO

- US 9,655,891 B1 USE OF ISOQUINOLINE DERIVATIVES FOR
DIABETIC WOUND HEALING
- US 9,707,222 B2 ISOQUINOLINEALKALOID DERIVATIVE FOR
ACTIVATING AMP-DEPENDENT PROTEINKINASE

1. GYT002 effectively decreases hepatic glucose for
type II DM through low dose. Fitting the potential
hypoglycemic agent invention trend for type II DM.。

2. GYT005, derived from GYT002, is highly efficiency
for wound-healing on diabetes.
The market value of GYT005 for wound-healing on
diabetes is estimated for US$10 billion per year.

The revenues of GYT002 and GYT005 are both
estimated to be at least 4 billion USD in new drugs
market per year.
Investments and related disease association are
welcomed.
For more informationvia: [email protected]

Market Value

R&D partnership

•National Taiwan University, College of Medicine

In last decade we have collaborated with the

•Taipei Medical University

following medical institutions：

•Development Center for Biotechnology

•Fu Jen Catholic University, College of Medicine